ArticleEuropean journal of clinical pharmacology2026
Population pharmacokinetic modeling of amisulpride drug interactions and a transporter binding analysis.
Article in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe combination of amisulpride and metformin is common in schizophrenia, but their potential drug-drug interaction has been largely overlooked, despite both drugs being prototypical substrates for renal elimination and potentially subject to transport by OCT2 and MATE1.
methodsIn this study, we employed population pharmacokinetic modeling to quantify the impact of renal function and metformin on amisulpride pharmacokinetics, and complemented it with molecular docking to predict binding modes on key renal transporters, thereby exploring potential transporters mediating the interaction.
resultsWe identified CLcr, assessed by the Cockcroft-Gault formula, as the dominant covariate. A 10% decrease in CLcr was associated with a 3.8% decrease in CL/F, while metformin significantly reduced clearance by 23.2%, leading to an at least 41% increase in amisulpride steady‑state trough concentration. Molecular docking generated a structural hypothesis that amisulpride and metformin may share overlapping binding sites on OCT2 and MATE1.
conclusionThis study provides the first clinical indication of a potential drug-drug interaction between amisulpride and metformin. We provide model‑informed dosing references stratified by CLcr, along with recommendations for dose reduction and heightened vigilance for interaction-related adverse effects in patients receiving combination therapy. Molecular docking offers a structural hypothesis regarding binding at OCT2 and MATE1 to support further mechanistic investigation.
Indexed as
Identifiers
42518010What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.